The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension

American Journal of Hypertension

Volumn 10, Issue 2, 1997, Pages 189-196

  Lacourcière, Yves ^a   Poirier, Luc ^a   Lefebvre, Jean ^a   Archambault, Francine ^a   Dalle Ave, Sonja ^b   Ward, Carol ^c   Lindberg, Elisabet ^c  

^a LAVAL UNIVERSITY   (Canada)

^b Hoffmann La Roche Ltd   (Canada)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

ambulatory blood pressure monitoring; mibefradil; moderate to severe hypertension; nifedipine

Indexed keywords

CALCIUM ANTAGONIST; LISINOPRIL; MIBEFRADIL; NIFEDIPINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; BODY WEIGHT; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIBEFRADIL; MIDDLE AGED; NIFEDIPINE; TETRAHYDRONAPHTHALENES;

EID: 0031081764     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(96)00322-6     Document Type: Article

References (32)

1. 1. Psaty B, Koepsell T, Yanez N: Temporal patterns of antihypertensive medication use among older adults, 1989-1992: an effect of major clinical trials on clinical practice? JAMA 1995;273:1436-1438.
2. 2. Osterrieder W, Holck M: In vitro pharmacologic profile of Ro 40-5967, a novel Ca++ channel blocker with potent vasodilator but weak inotropk action. J Cardiovasc Pharmacol 1989;13:754-759.
3. 3. Clozel J, Banken L, Osterrieder W: Effects of Ro 40-5967, a novel calcium calcium anagonist on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol 1989;14:713-721.
4. 4. Mishra S, Hermsmeyer K: Selective inhibition of T-type Ca++ channels by Ro 40-5967. Circ Res 1994;75:144-148.
5. 5. Rutledge A, Triggle D: The binding interactions of Ro 40-5967 at the L-type calcium channel in cardiac tissue. Eur J Pharmacol 1995;280:155-158.
6. 6. Clozel J, Osterrieder W, Kleinbloesen C, et al: Ro 40-5967: a new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991;9:4-17.
7. 7. Schmitt R, Kleinbloesen C, Belz G, et al: Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992;52:314-323.
8. 8. Veniant M, Clozel J, Hess P, Wolfgang R: Ro 40-5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 1991;17:277-284.
9. 9. Chapelle F, Stoleru L, Hayashida W, et al: Ro 40-5967, a new calcium antagoist profile: bradycardia without myocardial depression? (abst). Circulation 1994;90:139.
10. 10. Graettinger W, Lyson J, Cheung D, Weber M: Validation of portable noninvasive blood pressure monitoring devices: comparison with intra-arterial and sphygmomanometer measurements. Am Heart J 1988;16:1155-1160.
11. 11. Mancia G, Sega R, Bravi C, et al: Ambulatory blood pressure normality: results from the PAMELA study. J Hypertens 1995;13:1377-1390.
12. 12. Omboni S, Parati G, Zanchetti A, Mancia G: Calculation of trough: peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects. J Hypertens 1995;13:1105-1112.
13. 13. Zanchetti A, on behalf of the Italian Nifedipine GITS Study Group: Trough:peak ratio of the blood pressure response to dihydropyridine calcium antagonists. J Hypertens 1994;12:S97-S106.
14. 14. Murphy M, Bulpitt C, Dollery C: Role of nifedipine in the treatment of resistant hypertension: comparison with hydralazine in hospital outpatients. Am J Med 1984;77:16-21.
15. 15. Lacourcière Y, Poirier L, Lefebvre J, Burford R: Clinical efficacy of forced titrated doses of diltiazem extended-release: a placebo controlled study. Am J Hypertens 1995;8:282-286.
16. 16. Floras JS: Will knowing the variability of ambulatory blood pressure improve clinical outcome? An additional consideration in the critical evaluation of this technology. Clin Invest Med 1991;14:231-240.
17. 17. Parati G, Pomidossi G, Allini F, et al: Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. J Hypertens 1987;5:93-98.
18. 18. White WB, Schulman P, McCabe EJ, Dey HM: Average daily blood pressure determines cardiac function in patients with hypertension. JAMA 1989;261:873-877.
19. 19. Verdecchia P, Porcellati C, Schillaci G, et al: Ambulatory blood pressure: an independant predictor of prognosis in essential hypertension. Hypertension 1994; 24:793-801.
20. 20. Coats AJS: Benefits of ambulatory blood pressure monitoring in the design of antihypertensive drug trials. Blood Pressure Monitoring 1996;1:157-160.
21. 21. White WB: Clinical relevance of ambulatory versus clinic blood pressure when evaluating antihypertensive therapy. Blood Pressure Monitoring 1996;1:170-173.
22. 22. Lacourcière Y, Lefebvre J, Poirier L, et al: Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination: a randomized, double-blind, placebo-controlled, factorial design trial. Am J Hypertens 1994;7:137-145.
23. 23. Weber MA, Cheung DG, Graettinger WF, Lipson JL: Characterization of antihypertensive therapy by whole-day blood pressure monitoring. JAMA 1988;259:3281-3285.
24. 24. Staessen JA, O'Brien ET, Atkins N, Amery AK: Ambulatory blood pressure in normotensive compared with hypertensive subjects. J Hypertens 1993;11:1289-1297.
25. 25. Staessen JA, Fagard R, Lijnen P, et al: Ambulatory blood pressure and blood pressure measured at home: progress report on a population study. J Cardiovasc Pharmacol 1994;23:S5-S11.
26. 26. Rose M, McMahon F: Some problems with antihypertensive drug studies in the context of new guidelines. 1990;3:151-155.
27. 27. Ruzicka M, Leenen FH: Relevance of 24h blood pressure profile and sympathetic activity for outcome on short-versus long-acting 1,4-dihydropyridines. Am J Hypertens 1996;9:86-94.
28. 28. Muller JE, Tofler GH, Stone PH: Carcadian variation of triggers of onset of acute cardiovascular disease. Circulation 1989;79:733-743.
29. 29. Lewis J: Adverse reactions to calcium antagonists. Drugs 1983;25:196-222.
30. 30. Bakx L, Van der Wall E, Braun S, et al: Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter placebo-controlled study. Am Heart J 1995;130:748-757.
31. 31. Kannel WB, Kannel C, Paffenberger RS, Cupples LA: Heart rate and cardiovascular mortality: the Framingham study. Am Heart J 1987;112:1489-1494.
32. 32. Gillum RF, Markul DM, Felman JJ: Pulse rate, coronary heart disease and death: The NHANES I epidemiologic follow-up study. Am Heart J 1991;121:172-177.